K. Bair

发表

Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists.

W. Kaelin, S. Sharma, Y. Chen, 1999, Proceedings of the National Academy of Sciences of the United States of America.

Identification of E2F-1/Cyclin A antagonists.

S. Sharma, Y. Chen, T. Ramsey, 2001, Bioorganic & medicinal chemistry letters.

Protein-protein interactions: lessons learned.

S. Sharma, T. Ramsey, K. Bair, 2002, Current medicinal chemistry. Anti-cancer agents.

Identification of amides derived from 1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).

Karl H. Clodfelter, P. Bauer, N. Kley, 2013, Bioorganic & medicinal chemistry letters.

Selective Growth Inhibition of Tumor Cells by a Novel Histone Deacetylase Inhibitor, NVP-LAQ824

P. Atadja, D. Cohen, P. Lassota, 2004, Cancer Research.

TOTAL SYNTHESIS OF ()-ILLUDIN M

K. Bair, F. R. Kinder, 1994 .

Design, synthesis, and antitumor activity of bicyclic and isomeric analogues of illudin M

William Bauta, K. Bair, F. R. Kinder, 1996 .

2-((Arylmethyl)Amino)-1, 3-Propanediols (AMAPS); Discovery, Selection and Development of Four Clinical Candidates

K. Bair, 1992 .

Psammaplins from the sponge Pseudoceratina purpurea: inhibition of both histone deacetylase and DNA methyltransferase.

K. Bair, I. Piña, S. Remiszewski, 2003, The Journal of organic chemistry.

Crystal structure of Mcl-1 in complex with compound 65

K. Bair, D. Gotur, T. Herbertz, 2019 .

Synthesis and DNA binding properties of saturated distamycin analogues.

D. Boger, K. Bair, C. Woods, 2002, Bioorganic & medicinal chemistry letters.

N-hydroxy-3-phenyl-2-propenamides as novel inhibitors of human histone deacetylase with in vivo antitumor activity: discovery of (2E)-N-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2-propenamide (NVP-LAQ824).

P. Atadja, P. Lassota, K. Bair, 2003, Journal of medicinal chemistry.

Molecular basis of USP7 inhibition by selective small-molecule inhibitors

Elizabeth C. Townsend, Claire Heride, D. Komander, 2017, Nature.

Fragment-based identification of amides derived from trans-2-(pyridin-3-yl)cyclopropanecarboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).

Brandon J. Bravo, Qiang Zhao, N. Skelton, 2013, Journal of medicinal chemistry.

Molecular Approaches to Discover Marine Natural Product Anticancer Leads – An Update from a Drug Discovery Group Collaboration

W. Gerwick, K. Bair, P. Crews, 2003 .

Inhibiteurs de hdac8 bicyclique [6,6] fusionnée

K. Bair, A. Rudnitskaya, J. Thomason, 2016 .

Discovery and optimization of novel piperazines as potent inhibitors of fatty acid synthase (FASN).

David S. Millan, Mark T. Kershaw, K. Bair, 2019, Bioorganic & medicinal chemistry letters.

Effects of isomeric 2-(Arylmethylamino)-1,3-propanediols (AMAPs) and clinically established agents on macromolecular synthesis in P388 and MCF-7 cells

K. Bair, C. Carter, C. A. Carter, 1991, Investigational New Drugs.

(1-Pyrenylmethyl)amino alcohols, a new class of antitumor DNA intercalators. Discovery and initial amine side chain structure-activity studies.

K. Bair, D. D. Mckee, V. Knick, 1990, Journal of medicinal chemistry.

USES OF THE TRIFYL GROUP IN ORGANIC SYNTHESIS. A REVIEW

J. B. Hendrickson, R. Bergeron, K. Bair, 1977 .

New methods for the synthesis of triflones

J. B. Hendrickson, K. Bair, J. Hendrickson, 1977 .

Solid Phase Synthesis of β-Peptides via Arndt-Eistert Homologation of Fmoc-Protected Amino Acid Diazoketones

K. Bleicher, K. Bair, R. Marti, 1997 .

Discovery and Optimization of Quinolinone Derivatives as Potent, Selective and Orally Bioavailable mutant Isocitrate Dehydrogenase 1 (mIDH1) Inhibitors.

Mark T. Kershaw, S. Ashwell, K. Bair, 2019, Journal of medicinal chemistry.

Retrospective Review: Cancer Drug Development: Current Research and Patents - 1992 - Part 1

K. Bair, 1993 .

Total syntheses of bengamides B and E.

M. Green, S. Zabludoff, K. Bair, 2001, The Journal of organic chemistry.

The use of directed metalation reactions in the synthesis of unsymmetrical anthrones and anthraquinones. Synthesis of anthracyclinone precursors

K. Bair, J. Baldwin, 1978 .

2-[(arylmethyl) amino]-2-methyl-1,3-propanediol DNA intercalators. An examination of the effects of aromatic ring variation on antitumor activity and DNA binding.

C. W. Andrews, K. Bair, D. D. Mckee, 1991, Journal of medicinal chemistry.

Trifyl activation in organic synthesis

J. B. Hendrickson, K. Bair, D. Sternbach, 1977 .

Patent Update: Cancer Drug Development: Current Research and Patents - 1991 - Part 2

K. Bair, 1992 .

Bengamides revisited: new structures and antitumor studies.

K. Bair, P. Crews, R. Versace, 2001, The Journal of organic chemistry.

Structure-based identification of ureas as novel nicotinamide phosphoribosyltransferase (Nampt) inhibitors.

Karl H. Clodfelter, Zhongguo Wang, Mark Zak, 2013, Journal of medicinal chemistry.

Polyploidy induction as a consequence of topoisomerase inhibition. A flow cytometric assessment.

David John Adams, K. Bair, R. Zucker, 1991, Biochemical pharmacology.

USES OF THE TRIFYL (TRIFLUOROMETHANESULFONYL) GROUP IN ORGANIC SYNTHESIS. A REVIEW

J. B. Hendrickson, R. Bergeron, K. Bair, 1978 .

Conversion of triflones to ketones

J. B. Hendrickson, K. Bair, P. Keehn, 1977 .

Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway.

D. Livingston, H. Naegeli, A. Kung, 2004, Cancer cell.

Synthesis of Isodehydroilludin M

K. Bair, M. Shapiro, F. R. Kinder, 1998 .

Solid-phase total synthesis of polymyxin B1.

K. Bair, C. Fotsch, N. Chandramouli, 1999, The journal of peptide research : official journal of the American Peptide Society.

Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates.

Manfred Jung, W. Cornell, P. Atadja, 2002, Journal of medicinal chemistry.

Proteomics-based Target Identification

Sunkyu Kim, Hans Voshol, J. Decaprio, 2003, Journal of Biological Chemistry.

An efficient multiple-exposure analysis of the toxicity of crisnatol, a DNA intercalator in phase II clinical trials

K. Bair, R. Zucker, D. Adams, 1992, Investigational New Drugs.

Discovery of potent and efficacious urea-containing nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with reduced CYP2C9 inhibition properties.

Yang Xiao, Lei Zhang, Karl H. Clodfelter, 2013, Bioorganic & medicinal chemistry letters.

Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors.

N. Skelton, D. Sampath, K. Bair, 2016, Journal of medicinal chemistry.

Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility.

Karl H. Clodfelter, N. Skelton, D. Sampath, 2015, Bioorganic & medicinal chemistry letters.

Identification of 2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-derived ureas as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).

Yang Xiao, Lei Zhang, Deepak Sampath, 2013, Bioorganic & medicinal chemistry letters.

Discovery of potent and efficacious cyanoguanidine-containing nicotinamide phosphoribosyltransferase (Nampt) inhibitors.

Karl H. Clodfelter, Zhongguo Wang, Mark Zak, 2013, Bioorganic & medicinal chemistry letters.

Structure-based discovery of novel amide-containing nicotinamide phosphoribosyltransferase (nampt) inhibitors.

Karl H. Clodfelter, P. Bauer, N. Kley, 2013, Journal of medicinal chemistry.

Synthesis and antitumor activity of ester-modified analogues of bengamide B.

S. Zabludoff, K. Bair, P. Crews, 2001, Journal of medicinal chemistry.

Structural Basis for Resistance to Diverse Classes of NAMPT Inhibitors

D. Sampath, K. Bair, Weiru Wang, 2014, PloS one.

The addition of alkyllithium reagents to trans-cyclooctene. The facile elimination of lithium hydride in the cyclooctyl ring

K. Bair, C. Willis, R. D. Bach, 1974 .

Wittig modification of the Hofmann elimination reaction. Evidence for an .alpha.',.beta. mechanism

K. Bair, R. D. Bach, D. Andrzejewski, 1972 .

Structural and conformational requirements for high-affinity binding to the SH2 domain of Grb2(1).

P. Ettmayer, M. S. Martin, K. Bair, 1999, Journal of medicinal chemistry.

Vidalenolone, a novel phenolic metabolite from the tropical red alga Vidalia sp.

W. Gerwick, K. Bair, H. Yoo, 2002, Journal of natural products.

Limitations of the fluorescent probe viability assay.

K. Bair, R. Zucker, E. J. Massaro, 1989, Molecular toxicology.

Discovery of novel biaryl sulfonamide based Mcl-1 inhibitors.

K. Bair, D. Gotur, T. Herbertz, 2019, Bioorganic & medicinal chemistry letters.

Fragment-based identification of amides derived from trans-2-(pyridin-3-yl)cyclopropanecarboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).

Brandon J. Bravo, Qiang Zhao, N. Skelton, 2013, Journal of medicinal chemistry.